Front Cardiovasc Med. 2026 Jul 13;13:1791657. doi: 10.3389/fcvm.2026.1791657. eCollection 2026.
ABSTRACT
Cardiovascular and cerebrovascular diseases remain the leading cause of death worldwide. Myocardial infarction-associated transcript (MIAT), a type of long non-coding RNA, has been reported to exert regulatory functions across multiple diseases in studies, and may serve as a promising therapeutic candidate in certain pathological conditions. This review provides a comprehensive analysis of the basic characteristics of MIAT, the latest research advancements, its involvement in cardiovascular and cerebrovascular diseases, and its potential as a biomarker and therapeutic target. The objective is to summarize the current understanding and mechanisms of MIAT, offering further scientific evidence to support its role in the treatment of cardiovascular and cerebrovascular diseases associated with MIAT. Additionally, this review explores the challenges and practical considerations for the clinical application of MIAT, aiming to provide new perspectives on its clinical translation.
PMID:42516955 | PMC:PMC13402375 | DOI:10.3389/fcvm.2026.1791657